IGC Pharma Announces Equity Research Update by Alliance Global Partners

IGC Pharma (NYSE American: IGC) announced that Alliance Global Partners published an updated equity research report on February 10, 2026.

Rhea-AI Summary

IGC Pharma (NYSE American: IGC) announced that Alliance Global Partners published an updated equity research report on February 10, 2026. The report reiterates a Buy rating and sets a $3.00 price target per share. IGC disclaims endorsement and does not guarantee the report's accuracy.

Positive

• Alliance Global Partners reiterated a Buy rating on IGC
• Analyst price target $3.00 per share (dated February 10, 2026)

Negative

• IGC explicitly does not endorse or guarantee the analyst report's accuracy

Argus Feb 10 session

+3.79% close to close Open Argus

Details

News Market Reaction – IGC

On Feb 10, the day this news came out, IGC closed 3.79% above the previous close.

Data tracked by StockTitan Argus for the Feb 10 session.

Market Context

This announcement highlights external analyst coverage, with Alliance Global Partners reiterating a ...

Analysis

This announcement highlights external analyst coverage, with Alliance Global Partners reiterating a Buy rating and a $3.00 price target on IGC. It comes after months of steady Phase 2 trial advancement and a modest capital raise at $0.30 per share. Investors may track how future clinical milestones, additional financing activity, and utilization of the existing resale registration interact with analyst views to shape the company’s risk–reward profile.

Key Figures

Analyst price target: $3.00 per share Registered offering size: 779,997 shares Offering price: $0.30 per share +5 more

Analyst price target

$3.00 per share

Alliance Global Partners equity research update

Registered offering size

779,997 shares

Direct offering disclosed Jan 5, 2026

Offering price

$0.30 per share

Registered direct offering Jan 5, 2026

Gross proceeds

$234,000

Registered direct offering Jan 5, 2026

Shares outstanding pre-offer

95,038,026

As disclosed in 424B5 prospectus

Shares outstanding post-offer

95,818,023

As disclosed in 424B5 prospectus

Resale registration value

$200,000

Moran Global Strategies share purchase under S-3/A

Registered resale shares

978,235 shares

Amended resale registration statement S-3/A

Historical Context

5 past events · Latest: Feb 02

5 events

1. Feb 02

   Clinical trial update

   24h Move

   +1.5%

   Reached ~70% enrollment in Phase 2 CALMA trial for Alzheimer’s agitation.

2. Jan 22

   Clinical site addition

   24h Move

   +7.3%

   New Brooklyn clinical site added to CALMA Phase 2 to support enrollment.

3. Jan 12

   Clinical site expansion

   24h Move

   -0.1%

   Lightship network site added using hybrid model to broaden trial access.

4. Jan 06

   Corporate reporting change

   24h Move

   -1.3%

   Fiscal year-end shifted to Dec 31 to improve U.S. reporting comparability.

5. Jan 05

   Capital raise

   24h Move

   +0.6%

   Registered direct offering at $0.30 to fund IGC-AD1 Phase 2 development.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

equity research, price target

2 terms

equity research financial

"Alliance Global Partners ("AGP") has published an updated equity research report"

Equity research is the process of studying a publicly traded company's business, finances and market position to form an informed view on whether its stock is a good investment. Think of it as a detailed inspection and forecast — analysts gather facts, estimate future profits and risks, and then recommend buy, hold or sell; investors use these findings like a weather report to judge potential returns and risks before putting money into a stock.

price target financial

"The report reiterates a Buy rating and includes a price target of $3.00 per share."

A price target is an analyst’s estimate of the future value of a stock, typically expressed as a single number for a set time frame. It matters to investors because it acts like an expected selling price when appraising a house—helping people decide whether a stock looks cheap, fairly priced, or expensive compared with current market price and guiding buy, hold or sell decisions; it is an opinion, not a guarantee.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

POTOMAC, MARYLAND / ACCESS Newswire / February 10, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Alliance Global Partners ("AGP") has published an updated equity research report covering the Company.

The report reiterates a Buy rating and includes a price target of $3.00 per share. All statements, opinions, estimates, projections, and conclusions contained in analyst reports represent the views of the respective analysts and are not those of IGC Pharma. IGC does not endorse, adopt, or guarantee the accuracy or completeness of any analyst report and undertakes no obligation to update or correct the information.

A copy of the report may be obtained from AGP: Link.

About IGC Pharma (dba IGC):

IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Contact Information:

Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alliance Global Partners say about IGC (IGC) on February 10, 2026?

AGP reiterated a Buy rating with a $3.00 price target. According to the company, the report reflects AGP analyst views and IGC does not endorse or guarantee its accuracy.

Does IGC (IGC) endorse the AGP equity research report dated February 10, 2026?

No, IGC does not endorse or adopt the analyst report. According to the company, it disclaims responsibility for the report's accuracy or completeness.

How can investors obtain the AGP equity research report on IGC (IGC)?

Investors may obtain a copy directly from Alliance Global Partners. According to the company, the report is available from AGP via the link referenced in the announcement.

What is the significance of a $3.00 price target for IGC (IGC)?

A $3.00 price target represents AGP's analyst valuation for the stock. According to the company, this figure reflects AGP's projections and is not endorsed by IGC.

Will IGC (IGC) update or correct the AGP analyst report after publication?

No, IGC undertakes no obligation to update or correct analyst reports. According to the company, statements and projections remain the analysts' responsibility.